AU2018315056B2 - Methods for diagnosis of early stage heart failure - Google Patents

Methods for diagnosis of early stage heart failure Download PDF

Info

Publication number
AU2018315056B2
AU2018315056B2 AU2018315056A AU2018315056A AU2018315056B2 AU 2018315056 B2 AU2018315056 B2 AU 2018315056B2 AU 2018315056 A AU2018315056 A AU 2018315056A AU 2018315056 A AU2018315056 A AU 2018315056A AU 2018315056 B2 AU2018315056 B2 AU 2018315056B2
Authority
AU
Australia
Prior art keywords
heart failure
subject
biomarkers
biological sample
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018315056A
Other languages
English (en)
Other versions
AU2018315056A1 (en
Inventor
Chamindie Punyadeera
Benjamin Schulz
Xi Xhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queensland University of Technology QUT
Original Assignee
Queensland University of Technology QUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017903138A external-priority patent/AU2017903138A0/en
Application filed by Queensland University of Technology QUT filed Critical Queensland University of Technology QUT
Publication of AU2018315056A1 publication Critical patent/AU2018315056A1/en
Application granted granted Critical
Publication of AU2018315056B2 publication Critical patent/AU2018315056B2/en
Priority to AU2021232662A priority Critical patent/AU2021232662B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Electrotherapy Devices (AREA)
  • External Artificial Organs (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
AU2018315056A 2017-08-08 2018-08-08 Methods for diagnosis of early stage heart failure Active AU2018315056B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021232662A AU2021232662B2 (en) 2017-08-08 2021-09-13 Markers relating to early stage heart failure

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017903138A AU2017903138A0 (en) 2017-08-08 Methods for Diagnosis of Early Stage Heart Failure
AU2017903138 2017-08-08
PCT/AU2018/050827 WO2019028507A1 (en) 2017-08-08 2018-08-08 METHODS OF DIAGNOSING PRECOCUS STAGES OF CARDIAC INSUFFICIENCY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021232662A Division AU2021232662B2 (en) 2017-08-08 2021-09-13 Markers relating to early stage heart failure

Publications (2)

Publication Number Publication Date
AU2018315056A1 AU2018315056A1 (en) 2020-03-26
AU2018315056B2 true AU2018315056B2 (en) 2021-06-17

Family

ID=65273054

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018315056A Active AU2018315056B2 (en) 2017-08-08 2018-08-08 Methods for diagnosis of early stage heart failure
AU2021232662A Active AU2021232662B2 (en) 2017-08-08 2021-09-13 Markers relating to early stage heart failure

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021232662A Active AU2021232662B2 (en) 2017-08-08 2021-09-13 Markers relating to early stage heart failure

Country Status (6)

Country Link
US (1) US20200174021A1 (enExample)
EP (1) EP3665483A4 (enExample)
JP (1) JP7414281B2 (enExample)
CN (1) CN111465857A (enExample)
AU (2) AU2018315056B2 (enExample)
WO (1) WO2019028507A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021283390A1 (en) 2020-06-03 2023-01-19 Esn Cleer Biomarker identification for imminent and/or impending heart failure
CN115327129A (zh) * 2022-07-05 2022-11-11 上海交通大学医学院附属上海儿童医学中心 一种血浆分子标志物犬尿氨酸在早期心力衰竭检测中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133770A2 (en) * 2010-04-21 2011-10-27 Board Of Regents Of The University Of Texas System Salivary protein markers for detection of breast cancer
WO2013090811A1 (en) * 2011-12-14 2013-06-20 The Johns Hopkins University Biomarkers of pulmonary hypertension
US20150045245A1 (en) * 2011-12-08 2015-02-12 Biocartis Nv Biomarkers and test panels useful in systemic inflammatory conditions
WO2016134365A1 (en) * 2015-02-20 2016-08-25 The Johns Hopkins University Biomarkers of myocardial injury

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094870A2 (en) * 2000-11-02 2002-11-28 Curagen Corporation Proteins and nucleic acids encoding same
US20030113726A1 (en) * 2000-12-04 2003-06-19 Zenta Tsuchihashi Human single nucleotide polymorphisms
US20040033582A1 (en) * 2002-06-03 2004-02-19 Manling-Ma Edmonds Human single nucleotide polymorphisms
TW200413539A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Genes and polypeptides relating to prostate cancers
JP2005110602A (ja) 2003-10-09 2005-04-28 Sumitomo Pharmaceut Co Ltd アトピー性皮膚炎の疾患マーカー及びその利用
WO2006008002A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with kallikrein 1 (klk1)
WO2006015209A2 (en) * 2004-07-29 2006-02-09 Stem Cell Innovations, Inc. Differentiation of stem cells
EP1722232A1 (en) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Devices and methods for diagnosing or predicting early stage cardiac dysfunctions
WO2007047995A2 (en) * 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
JP2009541287A (ja) * 2006-06-20 2009-11-26 リポペプチド・アクチエボラーグ 抗癌剤としてのカテリシジン抗菌タンパク質（ｈＣＡＰ１８）の使用
WO2008000067A1 (en) * 2006-06-26 2008-01-03 Vasogen Ireland Limited Treatment of mild chronic heart failure in human patients
CA2791144C (en) * 2006-07-05 2019-04-09 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
DK2046951T5 (da) * 2006-07-05 2012-01-23 Catalyst Biosciences Inc Proteasesreeningsmetoder og proteaser identificeret dermed
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
US20100267052A1 (en) * 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
CA2671267A1 (en) * 2006-11-30 2008-06-05 Navigenics Inc. Genetic analysis systems and methods
ZA200903761B (en) * 2006-11-30 2010-08-25 Navigenics Inc Genetic analysis systems and methods
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
EP2671083A1 (en) * 2011-02-03 2013-12-11 Abbott Laboratories Methods of prognosis and diagnosis in chronic heart failure
US10131709B2 (en) * 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
EP2877213B1 (en) * 2012-07-25 2020-12-02 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
EP2885637B1 (en) 2012-08-15 2016-11-30 The Procter & Gamble Company Use of human ex vivo skin model in a method of identifying modulators of skin inflammation
WO2014193999A2 (en) * 2013-05-28 2014-12-04 Caris Science, Inc. Biomarker methods and compositions
CN104049082B (zh) * 2014-05-30 2016-03-16 华中科技大学同济医学院附属同济医院 人组织激肽释放酶活性检测试剂盒及其应用
CN105987998B (zh) * 2015-01-30 2017-12-29 江苏众红生物工程创药研究院有限公司 人组织激肽释放酶1elisa定量检测试剂盒

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133770A2 (en) * 2010-04-21 2011-10-27 Board Of Regents Of The University Of Texas System Salivary protein markers for detection of breast cancer
US20150045245A1 (en) * 2011-12-08 2015-02-12 Biocartis Nv Biomarkers and test panels useful in systemic inflammatory conditions
WO2013090811A1 (en) * 2011-12-14 2013-06-20 The Johns Hopkins University Biomarkers of pulmonary hypertension
WO2016134365A1 (en) * 2015-02-20 2016-08-25 The Johns Hopkins University Biomarkers of myocardial injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IQBAL, N. et al., "Cardiac biomarkers: new tools for heart failure management", Cardiovascular Diagnosis and Therapy, (2012), vol. 2, no. 2, pages 147 - 164 *

Also Published As

Publication number Publication date
US20200174021A1 (en) 2020-06-04
AU2021232662B2 (en) 2023-06-01
AU2018315056A1 (en) 2020-03-26
AU2021232662A1 (en) 2021-10-07
JP2020530120A (ja) 2020-10-15
EP3665483A1 (en) 2020-06-17
CN111465857A (zh) 2020-07-28
EP3665483A4 (en) 2021-07-14
JP7414281B2 (ja) 2024-01-16
WO2019028507A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
EP2353011B1 (en) Biomarker for the prediction of first adverse events
AU2021232662B2 (en) Markers relating to early stage heart failure
JP2017525970A (ja) 被験体において心不全を診断するための手段及び方法
US20090226937A1 (en) Methods for the Detection and Monitoring of Congestive Heart Failure
US20120129187A1 (en) Diagnostical use of peroxiredoxin 4
US11740245B2 (en) Mass spectrometry-based methods for the detection of circulating histones H3 and H2B in plasma from sepsis or septic shock (SS) patients
US10557860B2 (en) Circulating pulmonary hypertension biomarker
JP6595641B2 (ja) 心不全の診断
JP2020064051A (ja) 神経変性疾患の診断用ペプチドマーカー
JP5090332B2 (ja) 炎症及び感染症のためのバイオマーカーとしての短鎖ｓｒｌアルコールデヒドロゲナーゼ（ｄｈｒｓ４）の測定
Elmas et al. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease
CA2748852C (en) Biomarkers associated with nephropathy
Hoffmann et al. Division of Clinical Chemistry Department of Medicine University Medical Center Freiburg, Germany 2 Institute of Transfusion
HK1203611B (en) Prognosis of adverse events in patients with suspected chronic heart failure
HK1164999A (en) Biomarker for the prediction of first adverse events
HK1203611A1 (en) Prognosis of adverse events in patients with suspected chronic heart failure

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)